212 related articles for article (PubMed ID: 37260331)
21. Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial.
Hurvitz SA; Saura C; Oliveira M; Trudeau ME; Moy B; Delaloge S; Gradishar W; Kim SB; Haley B; Ryvo L; Dai MS; Milovanov V; Alarcón J; Kalmadi S; Cronemberger E; Souza C; Landeiro L; Bose R; Bebchuk J; Kabbinavar F; Bryce R; Keyvanjah K; Brufsky AM
Oncologist; 2021 Aug; 26(8):e1327-e1338. PubMed ID: 34028126
[TBL] [Abstract][Full Text] [Related]
22. A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis.
Liu Y; Wang W; Yin R; Zhang Y; Zhang Y; Zhang K; Pan H; Wang K; Lou G; Li G; Zhang R; Li K; Rao J; Zhang B; Wang Y; Wang Q; Gao Y; Li H
BMC Med; 2023 Sep; 21(1):376. PubMed ID: 37775744
[TBL] [Abstract][Full Text] [Related]
23. Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.
Prat A; Cheang MC; Galván P; Nuciforo P; Paré L; Adamo B; Muñoz M; Viladot M; Press MF; Gagnon R; Ellis C; Johnston S
JAMA Oncol; 2016 Oct; 2(10):1287-1294. PubMed ID: 27281556
[TBL] [Abstract][Full Text] [Related]
24. Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study.
Lin NU; Pegram M; Sahebjam S; Ibrahim N; Fung A; Cheng A; Nicholas A; Kirschbrown W; Kumthekar P
J Clin Oncol; 2021 Aug; 39(24):2667-2675. PubMed ID: 33945296
[TBL] [Abstract][Full Text] [Related]
25. Pyrotinib combining with radiotherapy on breast cancer with brain metastasis.
Ma X; Li Y; Zhao Z; Li L; Gao C; Liu D; Li B; Zhao B
Exp Biol Med (Maywood); 2023 Jan; 248(2):106-116. PubMed ID: 36533572
[TBL] [Abstract][Full Text] [Related]
26. A Phase II, Single-Arm Study of Apatinib and Oral Etoposide in Heavily Pre-Treated Metastatic Breast Cancer.
Hu N; Zhu A; Si Y; Yue J; Wang X; Wang J; Ma F; Xu B; Yuan P
Front Oncol; 2020; 10():565384. PubMed ID: 33659204
[TBL] [Abstract][Full Text] [Related]
27. High DCR and Better Survival in Patients with Advanced or Metastatic Gastric Cancer Receiving Anti-Angiogenic TKI plus Chemotherapy: A Real-World Study.
Nie C; Lv H; Chen B; Xu W; Wang J; Wang S; Liu Y; He Y; Zhao J; Chen X
Technol Cancer Res Treat; 2023; 22():15330338221150561. PubMed ID: 36632666
[No Abstract] [Full Text] [Related]
28. Tyrosine kinase inhibitors in HER2-positive breast cancer brain metastases: A systematic review and meta-analysis.
Yu Y; Huang K; Lin Y; Zhang J; Song C
Cancer Med; 2023 Jul; 12(14):15090-15100. PubMed ID: 37255389
[TBL] [Abstract][Full Text] [Related]
29. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis.
Curigliano G; Mueller V; Borges V; Hamilton E; Hurvitz S; Loi S; Murthy R; Okines A; Paplomata E; Cameron D; Carey LA; Gelmon K; Hortobagyi GN; Krop I; Loibl S; Pegram M; Slamon D; Ramos J; Feng W; Winer E
Ann Oncol; 2022 Mar; 33(3):321-329. PubMed ID: 34954044
[TBL] [Abstract][Full Text] [Related]
30. Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2).
Yang G; Xu H; Yang Y; Zhang S; Xu F; Hao X; Li J; Xing P; Hu X; Liu Y; Wang L; Lin L; Wang Z; Duan J; Wang J; Wang Y
BMC Med; 2022 Aug; 20(1):277. PubMed ID: 36031613
[TBL] [Abstract][Full Text] [Related]
31. Pyrotinib Treatment in Patients With HER2-positive Metastatic Breast Cancer and Brain Metastasis: Exploratory Final Analysis of Real-World, Multicenter Data.
Anwar M; Chen Q; Ouyang D; Wang S; Xie N; Ouyang Q; Fan P; Qian L; Chen G; Zhou E; Guo L; Gu X; Ding B; Yang X; Liu L; Deng C; Xiao Z; Li J; Wang Y; Zeng S; Hu J; Zhou W; Qiu B; Wang Z; Weng J; Liu M; Li Y; Tang T; Wang J; Zhang H; Dai B; Tang W; Wu T; Xiao M; Li X; Liu H; Li L; Yi W
Clin Cancer Res; 2021 Aug; 27(16):4634-4641. PubMed ID: 34112711
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of apatinib in patients with advanced nonsmall cell lung cancer that failed prior chemotherapy or EGFR-TKIs: A pooled analysis.
Ma JT; Sun J; Sun L; Zhang SL; Huang LT; Han CB
Medicine (Baltimore); 2018 Aug; 97(35):e12083. PubMed ID: 30170427
[TBL] [Abstract][Full Text] [Related]
33. Clinical outcomes of tucidinostat-based therapy after prior CDK4/6 inhibitor progression in hormone receptor-positive heavily pretreated metastatic breast cancer.
Zhou J; Wu X; Zhang H; Wang X; Yuan Y; Zhang S; Jiang Z; Wang T
Breast; 2022 Dec; 66():255-261. PubMed ID: 36375386
[TBL] [Abstract][Full Text] [Related]
34. Real-world efficacy and safety of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer center.
Sirvén MB; Fernández-Ortega A; Stradella A; Morilla I; Falo C; Vázquez S; Castany R; Villanueva R; Recalde S; Pérez VN; Gil-Gil M; Pernas S
BMC Pharmacol Toxicol; 2019 Nov; 20(1):68. PubMed ID: 31753013
[TBL] [Abstract][Full Text] [Related]
35. Phase II study of apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative metastatic breast cancer and clinical implications of monitoring ctDNA.
Zhu A; Yuan P; Hu N; Li M; Wang W; Wang X; Yue J; Wang J; Luo Y; Ma F; Zhang P; Li Q; Xu B; Cao S; Lippi G; Naito Y; Osman MA; Marta GN; Franceschini G; Orlandi A
Cancer Biol Med; 2021 May; 18(3):875-87. PubMed ID: 34037346
[TBL] [Abstract][Full Text] [Related]
36. A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer.
Larsen PB; Kümler I; Nielsen DL
Cancer Treat Rev; 2013 Nov; 39(7):720-7. PubMed ID: 23481218
[TBL] [Abstract][Full Text] [Related]
37. [Retrospective study on the efficacy and safety of low dose apatinib in reversing chemotherapy resistance in sarcoma].
Ye T; Yuan SY; Fan L; Feng LW; Chen YT; Chen J
Zhonghua Yi Xue Za Zhi; 2022 Aug; 102(31):2435-2440. PubMed ID: 36000372
[No Abstract] [Full Text] [Related]
38. TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.
Freedman RA; Gelman RS; Anders CK; Melisko ME; Parsons HA; Cropp AM; Silvestri K; Cotter CM; Componeschi KP; Marte JM; Connolly RM; Moy B; Van Poznak CH; Blackwell KL; Puhalla SL; Jankowitz RC; Smith KL; Ibrahim N; Moynihan TJ; O'Sullivan CC; Nangia J; Niravath P; Tung N; Pohlmann PR; Burns R; Rimawi MF; Krop IE; Wolff AC; Winer EP; Lin NU;
J Clin Oncol; 2019 May; 37(13):1081-1089. PubMed ID: 30860945
[TBL] [Abstract][Full Text] [Related]
39. Prognostic Factors and Survival According to Tumor Subtype in Women With Breast Cancer Brain Metastases.
Lopes S; Vieira I; Abreu M; Pousa I; Ferreira A; Sousa S; Pereira D
Curr Probl Cancer; 2022 Dec; 46(6):100866. PubMed ID: 36179388
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and Safety of Third-Line Apatinib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer Patients: A Multicenter, Retrospective, Cohort Study.
Fan W; Ding J; Zhong W
Tohoku J Exp Med; 2023 May; 260(1):13-20. PubMed ID: 36696982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
